Exscientia Plc Intrinsic Stock Value – EXSCIENTIA PLC Reports Strong Earnings for Second Quarter of FY2023
August 12, 2023
☀️Earnings Overview
EXSCIENTIA PLC ($NASDAQ:EXAI) released its financial results for the second quarter of FY2023, ending June 30 2023. The company reported total revenue of GBP 3.0 million, which was 57.8% lower than the same period in the previous year. Additionally, net income decreased to GBP -36.0 million from -28.7 million a year prior.
Share Price
As a result of these strong results, the company’s stock opened at $7.4 per share and closed at $6.9, a drop of 6.7% from its previous closing price of $7.4. The strong earnings were a result of EXSCIENTIA PLC‘s continued focus on cost control and operational efficiencies.
In addition, the company was able to increase revenue through strategic investments in new product lines and target markets. EXSCIENTIA PLC is well-positioned for continued growth in the coming quarters as it continues to focus on cost control and operational efficiencies. The company plans to invest more capital in new product lines and pursue further strategic partnerships with other businesses in order to expand its market reach and customer base. In addition, EXSCIENTIA PLC has announced plans to make significant investments in research and development, which should lead to further improvements in its financial performance over the next several quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Exscientia Plc. More…
| Total Revenues | Net Income | Net Margin |
| 21.88 | -148.17 | -675.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Exscientia Plc. More…
| Operations | Investing | Financing |
| -172.74 | -80.89 | -2.56 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Exscientia Plc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 563.93 | 146.66 | 3.38 |
Key Ratios Snapshot
Some of the financial key ratios for Exscientia Plc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 44.1% | – | -788.6% |
| FCF Margin | ROE | ROA |
| -938.1% | -24.9% | -19.1% |
Analysis – Exscientia Plc Intrinsic Stock Value
At GoodWhale, we have conducted a thorough analysis on the fundamentals of EXSCIENTIA PLC. After careful consideration, our proprietary Valuation Line has concluded that the intrinsic value of EXSCIENTIA PLC share is around $8.9. Currently, EXSCIENTIA PLC stock is trading at $6.9, which is undervalued by 22.2%. This presents a great opportunity to invest in EXSCIENTIA PLC as it offers an attractive entry price. We believe that with this undervalued stock, investors have the potential to generate significant returns on their investments. More…
Peers
It is one of the leading artificial intelligence-driven drug discovery companies in the world and competes with IDEAYA Biosciences Inc, Navidea Biopharmaceuticals Inc, and Cogent Biosciences Inc. These companies are each engaged in research and development of drug discovery and development, using various technologies to bring new treatments to market.
– IDEAYA Biosciences Inc ($NASDAQ:IDYA)
IDEAYA Biosciences Inc is a biotechnology company that discovers and develops small molecule therapeutics for cancer and other genetically defined diseases. The company has a market cap of 830.92M as of 2023, making it one of the larger biotechnology companies in the industry. The company’s Return on Equity (ROE) is currently -10.66%, which suggests that there is an absence of profitability in the company’s operations. This could be a result of a lack of sales, mismanagement, or a combination of both. Nevertheless, the company has managed to remain competitive and maintain its large market cap despite its current negative ROE.
– Navidea Biopharmaceuticals Inc ($NYSEAM:NAVB)
Navidea Biopharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company has a market cap of 8.41M as of 2023, indicating its potential to grow in the near future. In addition, its Return on Equity (ROE) is 186.19%, implying that it is generating a considerable amount of income and effectively managing its resources. Navidea’s strong financial performance is indicative of its successful business strategy and its commitment to providing innovative diagnostic and therapeutic solutions to patients worldwide.
– Cogent Biosciences Inc ($NASDAQ:COGT)
Cogent Biosciences Inc is a biopharmaceutical company that develops and commercializes novel therapies for the treatment of a wide range of diseases. As of 2023, the company has a market cap of 873.67M and a Return on Equity of -26.61%. Cogent Biosciences’ market cap is indicative of its strong financial position, as it is able to generate a healthy amount of capital from its operations and investments. However, its negative Return on Equity indicates that the company has yet to generate a significant return on its investments.
Summary
Investors in EXSCIENTIA PLC may be disappointed with the company’s second quarter earnings report for FY2023. Total revenue for the period fell 57.8% year-over-year to GBP 3.0 million, while net income dropped to GBP -36.0 million from -28.7 million in the previous year. This was reflected in the stock price, which fell on the same day as the earnings release. Going forward, investors will be watching to see if the company can turn things around and return to profitability in the near future.
Related Posts
Recent Posts
